Metabolic Syndrome in HIV/HCV Co-infected Patients

Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39–46. https://doi.org/10.1097/QAI.0000000000001014.

Centers for Disease Control and Prevention. HIV surveillance report, 2017; vol. 29. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2018. Accessed [June 1, 2019].

Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection–a trend analysis. J Infect Dis. 2017;216(12):1525–33. https://doi.org/10.1093/infdis/jix518.

Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24(5):697–706. https://doi.org/10.1097/QAD.0b013e3283365356.

Antiretroviral therapy cohort collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96. https://doi.org/10.1086/652283.

Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–97. https://doi.org/10.1093/cid/ciu701.

Cole MB, Galárraga O, Rahman M, Wilson IB. Trends in comorbid conditions among medicaid enrollees with HIV. Open Forum Infect Dis. 2019;6(4):ofz124. https://doi.org/10.1093/ofid/ofz124.

Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29(1):150–4. https://doi.org/10.1086/520144.

Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Multivirc Group Hepatol. 1999;30(4):1054–8. https://doi.org/10.1002/hep.510300409.

Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158(9):658–66. https://doi.org/10.7326/0003-4819-158-9-201305070-00604.

Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis. 2013;56(7):1038–43. https://doi.org/10.1093/cid/cis1206.

Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–9. https://doi.org/10.1086/321909.

Bedimo R, Abodunde O. Metabolic and cardiovascular complications in HIV/HCV-co-infected patients. Curr HIV/AIDS Rep. 2016;13(6):328–39. https://doi.org/10.1007/s11904-016-0333-9.

Slama L, Le Camus C, Serfaty L, Pialoux G, Capeau J, Gharakhanian S. Metabolic disorders and chronic viral disease: the case of HIV and HCV. Diabetes Metab. 2009;35(1):1–11. https://doi.org/10.1016/j.diabet.2008.08.003.

Freiberg MS, Chang C-CH, Skanderson M, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4(4):425–32. https://doi.org/10.1161/CIRCOUTCOMES.110.957415.

McKibben RA, Haberlen SA, Post WS, et al. A cross-sectional study of the association between chronic hepatitis C virus infection and subclinical coronary atherosclerosis among participants in the multicenter AIDS cohort study. J Infect Dis. 2016;213(2):257–65. https://doi.org/10.1093/infdis/jiv396.

Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int. 2017;37(Suppl 1):13–8. https://doi.org/10.1111/liv.13282.

Banks DE, Bogler Y, Bhuket T, Liu B, Wong RJ. Significant disparities in risks of diabetes mellitus and metabolic syndrome among chronic hepatitis C virus patients in the U.S. Diabetes Metab Syndr. 2017;11(Suppl 1):S153–8. https://doi.org/10.1016/j.dsx.2016.12.025.

Marks K, Naggie S. Management of Hepatitis C in 2019. JAMA. 2019. https://doi.org/10.1001/jama.2019.5353.

Collins LF, Chan A, Zheng J, et al. Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Open Forum Infect Dis. 2018;5(1):ofx264. https://doi.org/10.1093/ofid/ofx264.

Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents. 2019;53(5):559–63. https://doi.org/10.1016/j.ijantimicag.2018.11.024.

Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.

Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2008;48(3):272–80. https://doi.org/10.1097/QAI.0b013e31817af461.

Worm SW, Friis-Møller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24(3):427–35. https://doi.org/10.1097/QAD.0b013e328334344e.

Colaci M, Malatino L, Antonelli A, Fallahi P, Giuggioli D, Ferri C. Endocrine disorders associated with hepatitis C virus chronic infection. Rev Endocr Metab Disord. 2018;19(4):397–403. https://doi.org/10.1007/s11154-018-9475-y.

Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21(18):2445–53. https://doi.org/10.1097/QAD.0b013e3282efad32.

Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. Rev Endocr Metab Disord. 2018;19(4):405–20. https://doi.org/10.1007/s11154-017-9440-1.

Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416–23. https://doi.org/10.1053/j.gastro.2007.11.010.

Li X, Gao Y, Xu H, Hou J, Gao P. Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients. Sci Rep. 2017;7(1):9087. https://doi.org/10.1038/s41598-017-09825-7.

Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84(5):1513–7. https://doi.org/10.1210/jcem.84.5.5661.

Butt AA, Yan P, Chew KW, et al. Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES. Clin Infect Dis. 2017;65(4):557–65. https://doi.org/10.1093/cid/cix359.

Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology. 2016;150(1):145–155.e4; quiz e15-16. https://doi.org/10.1053/j.gastro.2015.09.007.

Leone S, Lorenzini P, Cozzi-Lepri A, et al. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. Eur J Clin Microbiol Infect Dis. 2019. https://doi.org/10.1007/s10096-019-03618-8.

Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, Weber R, Sabin C, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther (Lond). 2010;15(8):1077–86. https://doi.org/10.3851/IMP1681.

Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11(7):462–8. https://doi.org/10.1111/j.1468-1293.2009.00815.x.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9. https://doi.org/10.1001/jama.287.3.356.

Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, national health and nutrition examination survey, 1988–2012. Prev Chronic Dis. 2017;14. https://doi.org/10.5888/pcd14.160287.

Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427–36.

Hanley AJG, Williams K, Festa A, Wagenknecht LE, D’Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54(11):3140–7. https://doi.org/10.2337/diabetes.54.11.3140.

Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–74. https://doi.org/10.7326/0003-4819-140-3-200402030-00007.

Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335–44. https://doi.org/10.7326/M14-0954.

Lai H, Moore R, Celentano DD, et al. HIV Infection Itself May Not Be Associated With Subclinical Coronary Artery Disease Among African Americans Without Cardiovascular Symptoms. J Am Heart Assoc. 2016;5(3):e002529. https://doi.org/10.1161/JAHA.115.002529.

Lorenz DR, Dutta A, Mukerji SS, Holman A, Uno H, Gabuzda D. Marijuana use impacts midlife cardiovascular events in HIV-infected men. Clin Infect Dis. 2017;65(4):626–35. https://doi.org/10.1093/cid/cix391.

Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727–34. https://doi.org/10.1093/cid/cis933.

Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37(6):647–52. https://doi.org/10.1111/apt.12234.

Rafiq N, Stepanova M, Lam B, Nader F, Srishord M, Younossi ZM. Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. Ann Hepatol. 2013;13(1):60–4.

Kupin WL. Viral-associated GN: hepatitis C and HIV. Clin J Am Soc Nephrol. 2017;12(8):1337–42. https://doi.org/10.2215/CJN.04320416.

Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26(15):1907–15. https://doi.org/10.1097/QAD.0b013e328357f5ed.

Fischer MJ, Wyatt CM, Gordon K, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr. 2010;53(2):222–6. https://doi.org/10.1097/QAI.0b013e3181b980d4.

Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45(8):1074–81. https://doi.org/10.1086/521935.

Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37(2):292–8. https://doi.org/10.1086/375844.

Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045–52. https://doi.org/10.1210/jcem.74.5.1373735.

Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–82. https://doi.org/10.1001/jama.289.22.2978.

Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra A-B, ERCHIVES study team. Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis. 2015;15:510. https://doi.org/10.1186/s12879-015-1268-2.

Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS. 2007;21(1):71–6. https://doi.org/10.1097/QAD.0b013e3280110ada.

Patroni A, Torti C, Tomasoni L, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials. 2002;3(6):451–61. https://doi.org/10.1310/hct.2002.3.6.002.

Seaberg EC, Muñoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953–60. https://doi.org/10.1097/01.aids.0000171410.76607.f8.

van Zoest RA, Wit FW, Kooij KW, et al. Higher prevalence of hypertension in HIV-1-infected patients on combination antiretroviral therapy is associated with changes in body composition and prior Stavudine exposure. Clin Infect Dis. 2016;63(2):205–13. https://doi.org/10.1093/cid/ciw285.

Gelpi M, Afzal S, Lundgren J, et al. Higher risk of abdominal obesity, elevated low-density lipoprotein cholesterol, and hypertriglyceridemia, but not of hypertension, in people living with human immunodeficiency virus (HIV): results from the Copenhagen comorbidity in HIV infection study. Clin Infect Dis. 2018;67(4):579–86. https://doi.org/10.1093/cid/ciy146.

Herrin M, Tate JP, Akgün KM, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. 2016;73(2):228–36. https://doi.org/10.1097/QAI.0000000000001071.

Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33(4):506–12.

Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44(12):1625–31. https://doi.org/10.1086/518285.

Drozd DR, Kitahata MM, Althoff KN, et al. Increased risk of myocardial infarction in HIV-infected individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr. 2017;75(5):568–76. https://doi.org/10.1097/QAI.0000000000001450.

Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003. https://doi.org/10.1056/NEJMoa030218.

Piconi S, Parisotto S, Rizzardini G, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS. 2013;27(3):381–9. https://doi.org/10.1097/QAD.0b013e32835abcc9.

Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971–9. https://doi.org/10.1097/01.aids.0000060348.78202.74.

Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15(2):231–9.

Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J Acquir Immune Defic Syndr. 2008;48(1):53–62.

Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005;40(12):1837–45. https://doi.org/10.1086/430379.

Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab. 2003;88(2):627–36. https://doi.org/10.1210/jc.2002-020795.

Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(3):245–50.

Parrinello CM, Landay AL, Hodis HN, et al. Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women’s Interagency HIV study. AIDS. 2013;27(9):1516–9. https://doi.org/10.1097/QAD.0b013e32835fd8a9.

Lapadula G, Torti C, Paraninfo G, et al. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther (Lond). 2006;11(4):521–7.

Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179–84. https://doi.org/10.1001/archinte.165.10.1179.

De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224–9. https://doi.org/10.2337/dc07-2013.

DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–35. https://doi.org/10.1056/NEJMoa062744.

• Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of Tenofovir alafenamide (TAF) vs Tenofovir disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75(2):211–8. https://doi.org/10.1097/QAI.0000000000001350Results at 144 weeks of two double-blind phase three trials demonstrated superiority of tenofovir alafenamide- versus tenofovir disoproxil fumarate-backed initial HIV therapy with improved renal and bone safety indices in the tenofovir alafenamide group, however, increased lipid profiles.

Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3(4):e158–65. https://doi.org/10.1016/S2352-3018(16)00024-2.

Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455–65. https://doi.org/10.1097/QAD.0000000000002223.

Young J, Xiao Y, Moodie EEM, et al. Effect of cumulating exposure to Abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2015;69(4):413–21. https://doi.org/10.1097/QAI.0000000000000662.

Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318–30. https://doi.org/10.1086/649897.

Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61(4):441–7. https://doi.org/10.1097/QAI.0b013e31826f993c.

Milinkovic, Ana, Berger, Florian, Arenas-Pinto, Alejandro, Mauss, Stefan. Lipid changes associated with TAF are reversible by switching back to TDF. Presented at the: Conference on Retroviruses and Opportunistic Infections 2019; 2019; Seattle, WA.

Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60(12):1842–51. https://doi.org/10.1093/cid/civ193.

LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017;31(15):2095–106. https://doi.org/10.1097/QAD.0000000000001594.

Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291–300. https://doi.org/10.1016/S2352-3018(18)30043-2.

Muccini C, Galli L, Poli A, et al. Brief report: hyperbilirubinemia is associated with a decreased risk of carotid atherosclerosis in HIV-infected patients on virological suppression. J Acquir Immune Defic Syndr. 2018;79(5):617–23. https://doi.org/10.1097/QAI.0000000000001854.

Crane HM, Nance RM, Heckbert SR, et al. Association between Bilirubin, Atazanavir, and cardiovascular disease events among people living with HIV across the United States. J Acquir Immune Defic Syndr. 2019;81(5):e141–7. https://doi.org/10.1097/QAI.0000000000002071.

Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6):1056–74. https://doi.org/10.1086/381783.

Tebas P, Sension M, Arribas J, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis. 2014;59(3):425–34. https://doi.org/10.1093/cid/ciu234.

Thompson M, Orkin C, Molina J-M, et al. Once-daily doravirine for initial treatment of adults living with HIV-1: an integrated safety analysis. Clin Infect Dis. 2019. https://doi.org/10.1093/cid/ciz423.

•• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1902824This 96-week, phase three, open-label, randomized trial in South Africa comparing dolutegravir (with emtricitabine plus tenofovir alafenamide or tenofovir disoproxil fumarate) with efavirenz-based antiretroviral therapy showed significant weight gain in the dolutegravir group, especially when combined with tenofovir alafenamide and in female patients.

NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-dose Efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1904340.

Kerchberger AM, Sheth AN, Angert CD, et al. Integrase strand transfer inhibitors are associated with weight gain in women. Presented at the: Conference on Retroviruses and Opportunistic Infections 2019; 2019; Seattle, WA.

Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 2006;44(6):1026–32. https://doi.org/10.1016/j.jhep.2006.02.009.

Schaefer EAK, Chung RT. HCV and host lipids: an intimate connection. Semin Liver Dis. 2013;33(4):358–68. https://doi.org/10.1055/s-0033-1358524.

Morse CG, McLaughlin M, Matthews L, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):1569–78. https://doi.org/10.1093/cid/civ101.

Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44(1):47–55. https://doi.org/10.1016/j.jhep.2005.07.006.

Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(Suppl 2):13–25. https://doi.org/10.1111/j.1478-3231.2008.01952.x.

Lo JC, Kazemi MR, Hsue PY, et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis. 2005;41(9):1335–40. https://doi.org/10.1086/496981.

Hadigan C. Insulin resistance among HIV-infected patients: unraveling the mechanism. Clin Infect Dis. 2005;41(9):1341–2. https://doi.org/10.1086/496990.

• Reid M, Ma Y, Scherzer R, et al. Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults. AIDS. 2017;31(3):385–93. https://doi.org/10.1097/QAD.0000000000001345Generation of insulin resistance in HIV/HCV co-infection may be mediated by microbial gut translocation triggering inflammatory signaling cascades as evidenced by higher sCD163 levels.

Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71. https://doi.org/10.1038/nm1511.

Grunfeld C, Feingold KR. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDs. J Nutr. 1992;122(3 Suppl):749–53. https://doi.org/10.1093/jn/122.suppl_3.749.

Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199(1):79–86. https://doi.org/10.1016/j.atherosclerosis.2007.10.018.

Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7(12):1327–31. https://doi.org/10.1038/nm1201-1327.

Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49(Suppl 2):S79–85. https://doi.org/10.1097/QAI.0b013e318186519c.

Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol. 2017;5(4):343–62. https://doi.org/10.14218/JCTH.2017.00021.

Petta S, Amato M, Cabibi D, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology. 2010;52(5):1543–52. https://doi.org/10.1002/hep.23859.

Koethe JR, Hulgan T, Niswender K. Adipose Tissue and immune function: a review of evidence relevant to HIV infection. J Infect Dis. 2013;208(8):1194–201. https://doi.org/10.1093/infdis/jit324.

Lake JE. The fat of the matter: obesity and visceral adiposity in treated HIV infection. Curr HIV/AIDS Rep. 2017;14(6):211–9. https://doi.org/10.1007/s11904-017-0368-6.

Tien PC, Bacchetti P, Gripshover B, Overton ET, Rimland D, Kotler D. Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women. J Acquir Immune Defic Syndr. 2007;45(1):60–5. https://doi.org/10.1097/QAI.0b013e3180423a95.

• Breskin A, Westreich D, Cole SR, et al. The effects of hepatitis C infection and treatment on all-cause mortality among people living with human immunodeficiency virus. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy5Modeling the 10-year all-cause mortality in persons living with HIV after initiation of antiretroviral therapy showed a significant mortality benefit attributable to HCV elimination by direct-acting antivirals.

Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1–10. https://doi.org/10.1093/cid/cit757.

Moyer VA. Preventive services task force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(3):210–8. https://doi.org/10.7326/0003-4819-159-3-201308060-00652.

Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–6. https://doi.org/10.1093/cid/cir627.

Rhee MK, Ho Y-L, Raghavan S, et al. Random plasma glucose predicts the diagnosis of diabetes. PLoS One. 2019;14(7):e0219964. https://doi.org/10.1371/journal.pone.0219964.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed 24 Jul 2019.

Adinolfi LE, Nevola R, Guerrera B, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33(7):1379–82. https://doi.org/10.1111/jgh.14067.

Hum J, Jou JH, Green PK, et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care. 2017;40(9):1173–80. https://doi.org/10.2337/dc17-0485.

Gastaldi G, Gomes D, Schneiter P, et al. Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. PLoS One. 2019;14(6):e0217751. https://doi.org/10.1371/journal.pone.0217751.

Lim TR, Hazlehurst JM, Oprescu AI, et al. Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clin Endocrinol. 2019;90(3):440–8. https://doi.org/10.1111/cen.13924.

Meissner EG, Lee Y-J, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61(3):790–801. https://doi.org/10.1002/hep.27424.

Beig J, Orr D, Harrison B, Gane E. Hepatitis C virus eradication with new interferon-free treatment improves metabolic profile in hepatitis C virus-related liver transplant recipients. Liver Transpl. 2018;24(8):1031–9. https://doi.org/10.1002/lt.25060.

Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019. https://doi.org/10.1016/S2352-3018(19)30149-3.